Access Denied
Access Denied You don’t have permission to access ” on this server. Reference #18.4ef856b8.1768009422.5b82372e
Business
Read More
U.S. Hiring Continues at Modest Pace, but Weaknesses Are Evident
The unemployment rate fell in December, but job growth across 2025 was the lowest in five years.
Trump’s $100 Billion Venezuela Oil Plan Gets a Cool Reception
President Trump met with oil and gas executives on Friday in an effort to push them to invest money in Venezuela, a plan many of them are reluctant to embrace.
Stock market news for Jan. 9, 2026
Futures-options traders work on the floor at the New York Stock Exchange’s NYSE American (AMEX) in New York City, U.S., Jan. 7, 2026. Brendan McDermid | Reuters The S&P 500 rose to new highs on Friday, notching a weekly gain, following the release of the latest jobs report. The broad market index closed up 0.65%…
Regaining Momentum After a Holiday Break
While individuals might return feeling refreshed, organizations as a whole can lose focus.
Access Denied
Access Denied You don’t have permission to access ” on this server. Reference #18.e1cc517.1767979873.9eb67b02
Access Denied
Access Denied You don’t have permission to access ” on this server. Reference #18.4ef856b8.1767976194.5b4bd0b0
December’s Jobs Data Reinforces Fed’s Cautious Approach to Future Cuts
For the central bank to lower interest rates again, officials will likely need to see more notable signs that unemployment is rising.
Trump Is Making a Power Play in Latin America. China Is Already There.
China built a dominant strategic position in the region as the leading lender and trading partner. It is watching President Trump’s next moves closely.
Abivax’s stock surged to become a prime biotech takeover target
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600…